U.S. Markets closed

# Estimating The Intrinsic Value Of L'Occitane International S.A. (HKG:973)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of L'Occitane International S.A. (HKG:973) as an investment opportunity by taking the expected future cash flows and discounting them to today's value. I will be using the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

### Crunching the numbers

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:

#### 10-year free cash flow (FCF) estimate

 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Levered FCF (â‚¬, Millions) â‚¬119.5m â‚¬131.9m â‚¬149.5m â‚¬163.5m â‚¬175.2m â‚¬185.1m â‚¬193.4m â‚¬200.7m â‚¬207.2m â‚¬213.2m Growth Rate Estimate Source Analyst x6 Analyst x6 Analyst x4 Est @ 9.36% Est @ 7.15% Est @ 5.61% Est @ 4.53% Est @ 3.77% Est @ 3.24% Est @ 2.87% Present Value (â‚¬, Millions) Discounted @ 7.45% â‚¬111.2 â‚¬114.3 â‚¬120.5 â‚¬122.7 â‚¬122.4 â‚¬120.3 â‚¬117.0 â‚¬113.0 â‚¬108.6 â‚¬103.9

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF)= â‚¬1.2b

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 10-year government bond rate of 2%. We discount the terminal cash flows to today's value at a cost of equity of 7.4%.

Terminal Value (TV) = FCF2029 Ã— (1 + g) Ã· (r â€“ g) = â‚¬213m Ã— (1 + 2%) Ã· (7.4% â€“ 2%) = â‚¬4.0b

Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = â‚¬â‚¬4.0b Ã· ( 1 + 7.4%)10 = â‚¬1.95b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is â‚¬3.10b. The last step is to then divide the equity value by the number of shares outstanding. This results in an intrinsic value estimate in the companyâ€™s reported currency of â‚¬2.12. However, 973â€™s primary listing is in Luxembourg, and 1 share of 973 in EUR represents 8.698 ( EUR/ HKD) share of SEHK:973, so the intrinsic value per share in HKD is HK\$18.46. Relative to the current share price of HK\$16.12, the company appears about fair value at a 13% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

### The assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at L'Occitane International as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.4%, which is based on a levered beta of 0.913. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

### Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldnâ€™t be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For L'Occitane International, I've compiled three additional aspects you should further research:

1. Financial Health: Does 973 have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
2. Future Earnings: How does 973's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
3. Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of 973? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the HKG every day. If you want to find the calculation for other stocks just search here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.